February 2, 2011Open Access

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

Key Points

Key points are not available for this paper at this time.

Abstract

Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age. (Funded by Merck and others; ClinicalTrials.gov number, NCT00090285.).

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

Key Points

Abstract

Cite This Study